As Low As $0
Out of Pocket
co-pay-caret
XEOMIN® Efficacy - Chronic Sialorrhea

Adults With Chronic Sialorrhea

Disease
Overview
Clinical
Trial
Efficacy Safety Dosing

Proven Efficacy in Adults With Chronic Sialorrhea1

XEOMIN is the First and Only FDA-Approved Botulinum Toxin Type A for Adults With Chronic Sialorrhea

Proven Effective Over 16 Weeks Using Both Objective and Subjective Methods of Testing1

Improved salivary flow rate

A sustained reduction in patients’ saliva was observed over 16 weeks1

Improved salivary flow rate
Adult patients noticed an improvement in their chronic sialorrhea

Reference

  1. Jost W, Friedman A, Michel O, et al.SIAXI: Efficacy and safety of Xeomin (incobotulinumtoxinA) for the treatment of sialorrhea in Parkinson’s disease (PD) and other neurological conditions: results of a phase 3 study. Presented at: 70th Annual American Academy of Neurology Meeting; April 22, 2018.;Los Angeles, CA.